scoop.co.nz 12 Mar, 2021 17:45 am

Avance Clinical Client Atossa Therapeutics Announces Final Results From Phase 1 Clinical Study For AT-301 Nasal Spray

Avance Clinical Client Atossa Therapeutics Announces Final Results From Phase 1 Clinical Study For AT-301 Nasal Spray
Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19 ADELAIDE, AU, Mar 12, 2021 - (ACN Newswire) - The leading Australian ...

ADELAIDE, AU, Mar 12, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19.Yvonne Lungershausen, CEO, Avance Clinical said: "As the CRO for this important study, we congratulate Atossa Therapeutics on these impressive safety and tolerability clinical results.Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations.Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Read full story at scoop.co.nz